Zymeworks Inc.

NasdaqGS:ZYME Lagerbericht

Marktkapitalisierung: US$2.0b

Zymeworks Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Zymeworks wird ein jährliches Gewinn- und Umsatzwachstum von 30.8% bzw. 10.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 39.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 13.6% betragen.

Wichtige Informationen

30.8%

Wachstumsrate der Gewinne

39.42%

EPS-Wachstumsrate

Biotechs Gewinnwachstum23.4%
Wachstumsrate der Einnahmen10.7%
Zukünftige Eigenkapitalrendite13.65%
Analystenabdeckung

Good

Zuletzt aktualisiert29 Apr 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Zymeworks Inc. (NASDAQ:ZYME) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Nov 09
Zymeworks Inc. (NASDAQ:ZYME) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Recent updates

ZYME: Royalty Model Shift Will Rely On Upcoming HER2 Gastric Trial Data

Narrative Update on Zymeworks Analysts have lifted Zymeworks' implied price target range into the mid to high $40s, citing the $250m Royalty Pharma debt deal and a shift toward a more royalty focused model as key reasons for refining assumptions around profitability and a higher future P/E multiple. Analyst Commentary Recent Street research has been broadly constructive on Zymeworks, with several price target increases clustered in the mid to high $40s.

ZYME: Royalty Model Outlook Will Hinge On Upcoming HER2 Gastric Cancer Data

Analysts have raised Zymeworks’ fair value estimate from about $36.46 to $40.08, citing higher price targets in the $46 to $48 range, supportive views on the $250m Royalty Pharma financing, and a shift toward a more royalty-focused business model. Analyst Commentary Recent Street research has focused on Zymeworks’ financing decisions, its pivot toward a royalty-driven model, and the pipeline events that could influence how investors think about execution and valuation.

ZYME: Royalty Model Shift And FY26 Catalysts Will Drive Future Upside

Analysts have lifted their Zymeworks price target range into the mid $40s, citing the $250m Royalty Pharma financing and the company's tilt toward a more royalty-focused model, along with upcoming clinical and R&D milestones, as key supports for the higher valuations. Analyst Commentary Bullish analysts are clustering around price targets in the mid US$40s, reflecting a view that the recent US$250m Royalty Pharma financing and the pivot toward royalties could support higher valuations if execution stays on track.

ZYME: Royalty Model Shift And Debt Deal Will Drive Future Upside

Narrative Update: Zymeworks Analyst Price Target Shift The analyst price target for Zymeworks has moved from $48.27 to $55.34, with analysts pointing to the recent $250m Royalty Pharma debt deal, a more royalty-focused model, and upcoming clinical and R&D milestones as key factors supporting the higher valuation range cited in recent reports of $46 to $48. Analyst Commentary Bullish analysts are leaning into a more constructive view on Zymeworks, with several price targets now clustered in the mid to high US$40s range.

ZYME: Cancer Trial Success And Royalty Potential Will Drive Future Upside

Analysts have raised their price target on Zymeworks from $42.00 to approximately $48.27, citing updated assumptions around revenue growth, profit margins and future P/E expectations. What's in the News Chief Financial and Business Officer Leone Patterson plans to leave Zymeworks in the first quarter of 2026, with her role ending January 9, 2026, and employment concluding January 31, 2026 (company announcement).

ZYME: Royalty Model Will Be Supported By Upcoming HER2 Gastric Cancer Data

Analysts have raised their price targets on Zymeworks, with one firm moving to $40 from $37 and another to $25 from $17, citing the company's shift toward a royalty-focused model and expectations around upcoming HERIZON GEA-01 data as key drivers. Analyst Commentary Bullish Takeaways Bullish analysts point to the shift toward a royalty-focused model as a key reason for higher price targets, arguing that recurring royalty streams can support more visible revenue over time.

ADC And T Cell Engager Setbacks Will Test Reliance On Milestones Yet Offer Long-Term Upside

Catalysts About Zymeworks Zymeworks is a clinical stage biotechnology company focused on antibody drug conjugates, T cell engagers and partnered biologics for oncology and inflammatory diseases. What are the underlying business or industry changes driving this perspective?

ZYME: Royalty Model Will Be Driven By Positive HER2 Gastric Cancer Data

Narrative Update Analysts have nudged their blended price target for Zymeworks higher from about $34.50 to roughly $35.62 as they factor in the company’s shift toward a royalty-focused model around zani, positive HERIZON-GEA data for Ziihera, and updated views on future profitability and P/E assumptions. Analyst Commentary Street research on Zymeworks is clustering around two main themes: the shift toward a royalty-focused model centered on zani, and the impact of recent clinical data for Ziihera and early pipeline assets.

ZYME: Royalty Model And Cancer Data Will Drive Future Upside

Analysts have lifted their price targets on Zymeworks into a US$25 to US$42 range, citing the shift toward a royalty-focused model, positive HERIZON-GEA-01 data for Ziihera and Zani, and early but encouraging readouts for ZW191 and ZW251 as key drivers of their updated views. Analyst Commentary Bullish analysts are reacting positively to Zymeworks' shift toward a royalty-focused model and the recent clinical updates for Ziihera, Zani, ZW191, and ZW251.

HERIZON-GEA-01 Trial Highlights Zymeworks' Path To $440M Milestones And Growth

Jan 12

ZYME: Royalty Aggregator Model And Cancer Data Will Drive Future Upside

Analysts have lifted their price targets on Zymeworks into a roughly US$25 to US$42 range, reflecting their views on the company’s shift toward a royalty-focused model, positive HERIZON-GEA-01 data around Ziihera and Zani, and early ZW191 results that feed into higher assumed profit margins and a richer future P/E multiple in updated models. Analyst Commentary Recent Street research on Zymeworks has been broadly constructive, with several firms revisiting their models after the shift toward a royalty-focused setup and fresh clinical data around Ziihera, Zani and ZW191.

ZYME: Royalty Model And Cancer Data Will Drive Share Outperformance

The analyst fair value estimate for Zymeworks has been raised from $30.00 to $42.00 per share, as analysts point to stronger than expected HERIZON-GEA-01 efficacy data, an expanding royalty-driven model, and upgraded Street price targets as key drivers of higher growth and margin assumptions. Analyst Commentary Bullish analysts are increasingly framing Zymeworks as a higher quality growth story, citing a transition toward a recurring, royalty-driven revenue model and stronger than expected efficacy data from HERIZON GEA-01.

ZYME: Royalty Model Will Benefit From Positive HER2 Gastric Cancer Data

Analysts nudged their fair value estimate for Zymeworks slightly higher, from $34.20 to $34.50. This reflects growing confidence that the company’s shift toward a royalty aggregator model, coupled with strong HERIZON-GEA-01 data for Ziihera and encouraging early ZW191 results, can drive faster revenue growth and improved profitability.

ZYME: Recurring Royalty Revenue Will Drive Momentum After Positive Clinical Results

Zymeworks' analyst price target has surged from approximately $24.45 to $34.20 per share. This increase reflects analysts' optimism following the company's positive clinical trial results and strategic shift toward generating recurring royalty revenues.

Zymeworks Inc.'s (NASDAQ:ZYME) Shares Climb 30% But Its Business Is Yet to Catch Up

Nov 18
Zymeworks Inc.'s (NASDAQ:ZYME) Shares Climb 30% But Its Business Is Yet to Catch Up

Zymeworks Inc. (NASDAQ:ZYME) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Nov 09
Zymeworks Inc. (NASDAQ:ZYME) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

ZYME: Encouraging Pipeline Data Will Drive Momentum Ahead Of Key Clinical Readouts

Analysts have raised their price target for Zymeworks from $23.68 to $24.45 per share. They cite increased confidence in the company's growth outlook following encouraging clinical data and expanding therapeutic opportunities.

Analysts Raise Zymeworks Target on Pipeline Progress While Weighing Risks and Valuation Changes

Analysts have increased their price target for Zymeworks from $21.45 to $23.68 per share. They cite the company's differentiated therapies and upcoming clinical milestones as key drivers for the revised outlook.

Oncology And Biologic Therapies Will Unlock Global Opportunities

Analysts have increased their price target for Zymeworks from $20.06 to $21.45, citing improving revenue growth forecasts, stronger projected profit margins, and growing confidence in the momentum of Zanidatamab in biliary tract cancer. Analyst Commentary Recent commentary from street research reflects a mix of optimism and caution surrounding Zymeworks, particularly as the company advances its lead asset, Zanidatamab, in the biliary tract cancer market.

Oncology And Biologic Therapies Will Unlock Global Opportunities

Despite raised analyst confidence driven by positive clinical momentum for Zanidatamab and anticipated catalysts, Zymeworks’ consensus analyst price target has been modestly lowered from $21.05 to $20.06. Analyst Commentary Positive momentum for Zanidatamab in biliary tract cancer.

Optimistic Investors Push Zymeworks Inc. (NASDAQ:ZYME) Shares Up 25% But Growth Is Lacking

Sep 07
Optimistic Investors Push Zymeworks Inc. (NASDAQ:ZYME) Shares Up 25% But Growth Is Lacking

Zymeworks Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates

Aug 10
Zymeworks Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates

There's Reason For Concern Over Zymeworks Inc.'s (NASDAQ:ZYME) Price

Jun 18
There's Reason For Concern Over Zymeworks Inc.'s (NASDAQ:ZYME) Price

Analysts Just Shipped A Stunning Upgrade To Their Zymeworks Inc. (NASDAQ:ZYME) Estimates

May 14
Analysts Just Shipped A Stunning Upgrade To Their Zymeworks Inc. (NASDAQ:ZYME) Estimates

Zymeworks: Poised For Growth With Platform Validation

Apr 28

We're Hopeful That Zymeworks (NASDAQ:ZYME) Will Use Its Cash Wisely

Apr 16
We're Hopeful That Zymeworks (NASDAQ:ZYME) Will Use Its Cash Wisely
User avatar

Ziihera Launch And ZW251 IND Submission Will Broaden Treatment Options

Strategic focus on advanced programs and cost management aims to enhance resource efficiency and net margins through promising returns.

Industry Analysts Just Upgraded Their Zymeworks Inc. (NASDAQ:ZYME) Revenue Forecasts By 13%

Mar 11
Industry Analysts Just Upgraded Their Zymeworks Inc. (NASDAQ:ZYME) Revenue Forecasts By 13%

Zymeworks Inc.'s (NASDAQ:ZYME) Business Is Yet to Catch Up With Its Share Price

Feb 28
Zymeworks Inc.'s (NASDAQ:ZYME) Business Is Yet to Catch Up With Its Share Price

Zymeworks: Its Post-Approval Future

Feb 10

Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule

Dec 19

Companies Like Zymeworks (NASDAQ:ZYME) Are In A Position To Invest In Growth

Dec 13
Companies Like Zymeworks (NASDAQ:ZYME) Are In A Position To Invest In Growth

Optimistic Investors Push Zymeworks Inc. (NASDAQ:ZYME) Shares Up 34% But Growth Is Lacking

Nov 08
Optimistic Investors Push Zymeworks Inc. (NASDAQ:ZYME) Shares Up 34% But Growth Is Lacking

Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab

Nov 04

Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Nov 03
Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:ZYME - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/2028184-220358
12/31/2027210-3-41-1011
12/31/20262981291057412
12/31/2025106-81-35-33N/A
9/30/2025134-63-66-64N/A
6/30/2025123-74-41-39N/A
3/31/202593-114-79-76N/A
12/31/202476-123-113-110N/A
9/30/202462-114-59-55N/A
6/30/202463-113-96-91N/A
3/31/202450-126-77-73N/A
12/31/202376-119-122-118N/A
9/30/2023462205192195N/A
6/30/2023448186159165N/A
3/31/2023446173108116N/A
12/31/2022412124131144N/A
9/30/202230-224-252-234N/A
6/30/202232-237-231-212N/A
3/31/202228-240-224-207N/A
12/31/202127-212-206-192N/A
9/30/202122-211-199-190N/A
6/30/202121-223-161-155N/A
3/31/202131-194-161-155N/A
12/31/202039-181-158-151N/A
9/30/202025-215-147-140N/A
6/30/202030-173-150-135N/A
3/31/202026-163-113-98N/A
12/31/201930-145-96-82N/A
9/30/201957-64N/A5N/A
6/30/201951-52N/A3N/A
3/31/201965-29N/A20N/A
12/31/201853-37N/A24N/A
9/30/201874-13N/A13N/A
6/30/201872-11N/A14N/A
3/31/201852-16N/A-5N/A
12/31/201752-11N/A0N/A
9/30/20174-55N/A-47N/A
6/30/20176-51N/A-50N/A
3/31/201711-47N/A-41N/A
12/31/201611-34N/A-35N/A
9/30/201610-30N/A-32N/A
12/31/201510-19N/A-22N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ZYME wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (3.4%).

Ertrag vs. Markt: ZYME wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: ZYME wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: ZYMEDie Einnahmen des Unternehmens (10.7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (11.1% pro Jahr).

Hohe Wachstumseinnahmen: ZYMEDie Einnahmen des Unternehmens (10.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ZYMEDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (13.6%).

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/03 21:17
Aktienkurs zum Tagesende2026/05/01 00:00
Gewinne2025/12/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Zymeworks Inc. wird von 21 Analysten beobachtet. 12 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Tania Armstrong-WhitworthATB Cormark Historical (Cormark Securities)
David MartinBloom Burton & Co.
Mayank MamtaniB. Riley Securities, Inc.